



## Drug Coverage Policy

Effective Date ..... 7/15/2025

Coverage Policy Number ..... IP0042

Policy Title ..... Fintepla

## Antiseizure Medications – Fintepla

- Fintepla® (fenfluramine oral solution – Zogenix)

---

### INSTRUCTIONS FOR USE

*The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.*

---

### OVERVIEW

Fintepla, a serotonin 5-hydroxytryptamine subtype 2 (5-HT<sub>2</sub>) agonist, is indicated in patients ≥ 2 years of age for the treatment of **seizures associated with:**<sup>1</sup>

- **Dravet syndrome.**
- **Lennox-Gastaut syndrome.**

### Disease Overview

Dravet syndrome is a rare genetic epileptic encephalopathy (dysfunction of the brain) marked with frequent and/or prolonged seizures.<sup>2,3</sup> It is estimated that 1 out of 15,700 infants born in the US are affected with Dravet syndrome. The seizures generally begin in the first year of life in an otherwise healthy infant. Affected individuals can develop many seizure types: myoclonic, tonic-clonic, absence, atypical absence, atonic, focal aware or impaired awareness (previously called partial seizures), and status epilepticus.<sup>3</sup> As the seizures continue, most of the children develop some level of developmental disability and other conditions associated with the syndrome. Two or more antiseizure medications (ASMs) are often needed to control the seizures; most of the seizures are refractory to medications. The goals of treatment are cessation of prolonged convulsions, reductions in overall seizure frequency, and minimization of treatment side effects.<sup>4,5</sup> Some patients respond to the ketogenic diet and/or vagus nerve stimulation.

Lennox-Gastaut syndrome, a severe epileptic and developmental encephalopathy, is associated with a high rate of morbidity and mortality.<sup>6,7</sup> Lennox-Gastaut syndrome most often begins between 3 and 5 years of age.<sup>6-9</sup> Affected children experience several different types of seizures, most commonly atonic seizures (sudden loss of muscle tone and limpness) and tonic seizures.<sup>6,9</sup> The three main forms of treatment of Lennox-Gastaut syndrome are ASMs, dietary therapy (typically the ketogenic diet), and device/surgery (e.g., vagus nerve stimulation, corpus callostomy).<sup>9</sup> None of the therapies are effective in all cases of Lennox-Gastaut syndrome and the disorder has proven particularly resistant to most therapeutic options.

## **Guidelines**

### **Dravet Syndrome**

At this time, there are three drugs approved for the treatment of seizures associated with Dravet syndrome: Diacomit® (stiripentol capsules, powder for oral suspension), Epidiolex® (cannabidiol oral solution), and Fintepla.<sup>1,10</sup> An expert panel considers valproic acid to be the first-line treatment for Dravet syndrome.<sup>4</sup> Clobazam, Diacomit, and Fintepla can be considered as either first- or second-line ASMs. Cannabidiol was supported either as first- or second-line treatment. There was modest consensus among caregivers, but no consensus among physicians to support topiramate as first-, second-, or third-line therapy. The Dravet Foundation states that Diacomit, Epidiolex, and Fintepla are considered first-line agents for the treatment of Dravet syndrome.<sup>2</sup> If control is still inadequate, other therapies to consider are clonazepam, levetiracetam, and zonisamide.<sup>2,4</sup> Sodium channel blockers (e.g., carbamazepine, oxcarbazepine, lamotrigine, and phenytoin) can worsen seizures in Dravet syndrome. Additionally, vigabatrin and tiagabine may increase the frequency of myoclonic seizures and should be avoided.

### **Lennox-Gastaut Syndrome**

Currently, the FDA-approved drugs for this condition are Fintepla, clobazam, clonazepam, rufinamide, Epidiolex, felbamate, lamotrigine, and topiramate.<sup>8</sup> To address the lack of treatment algorithm, the Lennox-Gastaut syndrome Special Interest Group of the Pediatric Epilepsy Research Consortium (PERC) formed a core working group focused on ASM selection in this patient population (2025). Despite the lack of specific FDA labeling for Lennox-Gastaut syndrome, valproic acid remains a mainstay in treatment.<sup>8,9</sup> Valproic acid is considered a first-line pharmacological therapy but should be avoided in women of childbearing potential due to potential teratogenic effects.<sup>8</sup> Clobazam is recommended as a first-line option, particularly for managing disabling drop seizures, while it may be considered a second-line option in other cases. Cannabidiol may be considered a second-line therapy, specifically when combined with clobazam; otherwise, it is generally listed as a third-line treatment. Lamotrigine is considered a second-line therapy when used alongside valproate to enhance therapeutic synergy or in patients at risk of cognitive and behavioral side effects; otherwise, it can be utilized as a third- or fourth-line therapy depending on individual patient profiles. Rufinamide is a second-line option, particularly in cases where valproate or clobazam must be avoided, though it may be used as a third- or fourth-line option if these medications are tolerated. Topiramate can be considered from second- to fourth-line therapy, depending on the patient's

cognitive profile, as well as the suitability and availability of other ASMs. Additional later-line options include levetiracetam, brivaracetam, Fycompa® (perampanel tablet, oral suspension), zonisamide, fenfluramine, and felbamate. In managing Lennox-Gastaut syndrome, monotherapy is rarely effective, which necessitates the use of combination therapy with two or three ASMs with varying mechanisms of action. However, where possible, no more than two ASMs should be used concomitantly; use of multiple ASMs raise the risk of side effects and/or drug-drug interactions. In addition to pharmacological options, non-pharmacological therapies offer significant benefits in managing Lennox-Gastaut syndrome and include neuromodulation, resective surgery, corpus callosotomy, and the ketogenic diet.

## Coverage Policy

### POLICY STATEMENT

Prior Authorization is required for prescription benefit coverage of Fintepla. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Fintepla as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Fintepla to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Fintepla is considered medically necessary when ONE of the following are met:**

### FDA-Approved Indications

- 1. Dravet Syndrome.** Approve if the patient meets ONE the following (A or B):
  - A) Initial Therapy.** Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):
    - i.** Patient is  $\geq 2$  years of age; AND
    - ii.** Patient meets ONE of the following (a or b):
      - a)** Patient has tried or is concomitantly receiving at least two other antiseizure medications; OR  
Note: Examples of other antiseizure medications include valproic acid, topiramate, clonazepam, levetiracetam, zonisamide.
      - b)** Patient has tried or is concomitantly receiving one of clobazam, Epidiolex or Diacomit; AND
    - iii.** Fintepla is prescribed by or consultation with a neurologist; OR
  - B) Patient is Currently Receiving Fintepla.** Approve for 1 year if the patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.
- 2. Lennox-Gastaut Syndrome.** Approve if the patient meets ONE of the following (A or B):
  - A) Initial Therapy.** Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):
    - i.** Patient is  $\geq 2$  years of age; AND
    - ii.** Patient has tried or is concomitantly receiving at least two other antiseizure medications; AND  
Note: Examples of other antiseizure medications include clobazam, Epidiolex, felbamate, lamotrigine, rufinamide, topiramate, valproic acid, levetiracetam, zonisamide, Fycompa, vigabatrin.
    - iii.** The medication is prescribed by or in consultation with a neurologist.
  - B) Patient is Currently Receiving Fintepla.** Approve for 1 year if the patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Note: Receipt of sample product does not satisfy any criteria requirements for coverage.

**Conditions Not Covered**

**Fintepla for any other use is considered not medically necessary. Criteria will be updated as new published data are available.**

**References**

1. Fintepla® oral solution [prescribing information]. Emeryville, CA: Zogenix; April 2025.
2. Dravet Foundation – Dravet Syndrome. Available at: <https://www.dravetfoundation.org/what-is-dravet-syndrome/>. Accessed on April 21, 2025.
3. Shafer PO. Epilepsy Foundation – Dravet Syndrome. Updated August 2020. Available at: <http://www.epilepsy.com/learn/types-epilepsy-syndromes/dravet-syndrome>. Accessed on April 21, 2025.
4. Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. *Epilepsia*. 2022;63(7):1761-1777.
5. Knupp KG1, Wirrell EC. Treatment Strategies for Dravet Syndrome. *CNS Drugs*. 2018;32(4):335-350.
6. Sirven JI, Shafer PO. Epilepsy Foundation – Lennox-Gastaut Syndrome. Updated February 2020. Available at: <https://www.epilepsy.com/learn/types-epilepsy-syndromes/lennox-gastaut-syndrome-lgs>. Accessed on April 21, 2025.
7. Cross JH, Auvin S, Falip M, et al. Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. *Front Neurol*. 2017;8:505.
8. Samanta D, Bhalla S, Bhatia S, et al. Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. *Epilepsy Behav*. 2025;164:110261..
9. Wheless JW. National Organization for Rare Diseases (NORD) – Lennox-Gastaut syndrome. Updated May 20, 2024. Available at: <https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/#standard-therapies>. Accessed on April 21, 2025.
10. Diacomit® capsules, powder for oral suspension [prescribing information]. Redwood City, CA: Bicodex; July 2022.
11. Lennox-Gastaut Syndrome Foundation – Lennox-Gastaut Syndrome. Updated October 25, 2024. Available at: <https://www.lgsfoundation.org/about-lgs-2/what-is-lennox-gastaut-syndrome/>. Accessed on April 21, 2025.

**Revision Details**

Type of Revision	Summary of Changes	Date
Annual Revision	<b>Dravet Syndrome, Lennox-Gastaut Syndrome.</b> <b>Updated</b> terminology used for alternative therapy requirement <b>Added</b> 'Patient is Currently Receiving Fintepla' criteria  Title change from Fenfluramine.	8/1/2024

Annual Revision	<b>No content changes</b>	7/15/2025
-----------------	---------------------------	-----------

The policy effective date is in force until updated or retired.

---

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.